Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of QLS7305 in complement-mediated glomerular diseases
CTR20262538Phase 2Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Jul 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of QLS7305 in IgA nephropathy (IgAN), Complement 3 glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), idiopathic membranous glomerulonephritis (IMG), sponsored by Qilu Pharmaceutical. Started Jul 2026; status: active.
02
Drugs
QLS7305
03
Conditions
IgA nephropathy (IgAN)Complement 3 glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on CTR20262538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262538.